Endometrial immune profiling: a new perspective for pregnancy morbidity risk assessment in systemic lupus erythematosus - a pilot study

Endometrial immune profiling: a new perspective for pregnancy morbidity risk assessment in systemic lupus erythematosus - a pilot study - Endometrial immune profiling in SLE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56787

Enrollment

Registered

2024-04-17

Start date

2024-08-03

Completion date

Unknown

Last updated

2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lupus SLE

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: SLE patients - Fulfilling ACR or SLICC or EULAR/ACR criteria for SLE - No use of hormonal or intrauterine device anti-contraceptive - Premenopausal - Written informed consent - > 18 years old and *wilsbekwaam* Healthy women - No systemic autoimmune disease - No use of hormonal or intrauterine device anti-contraceptive - Premenopausal - Written informed consent - > 18 years old and *wilsbekwaam*

Exclusion criteria

Exclusion criteria: - Other autoimmune diseases - History of abnormal uterine cavity, major gynaecological surgery such as hysterectomy or salpingectomy,, endometriosis or previous reproductive-assisted invasive therapy - Malignancies - In case of healthy controls: repeated pregnancy loss or known difficulties to become pregnant (infertility)

Design outcomes

Primary

Measure	Time frame
Differences between immune cell subsets in menstrual blood in SLE compared to healthy controls	—

Secondary

Measure	Time frame
Differences between immune cell subsets in peripheral blood in SLE compared to healthy controls MxA levels as marker for interferon production NET formation Different cytokine levels in menstrual and peripheral blood	—

Countries

Netherlands

Outcome results